Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104898 | 0.88 | GLA (0.46) | CLK4CTSSCTSK | |
| SCHEMBL12919972 | 0.87 | ADAMTS4 (0.48) | CLK4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24726522 | 0.87 | RXRA (0.54) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL28747372 | 0.86 | CLK4 (0.46) | CLK4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10022432 | 0.84 | CYP11B1 (0.49) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL2154026 | 0.82 | CLK4 (0.65) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5352034 | 0.82 | RXRA (0.62) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL18977756 | 0.81 | CLK4 (0.49) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL598181 | 0.80 | RXRA (0.66) | RXRARXRBRXRGCTSSCTSK | |
| SCHEMBL27787243 | 0.80 | CLK4 (0.63) | CLK4GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-2022234965-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2022-11-10 | — | — | WO | disclosed |
| US-8202854-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012960-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1896477-B1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORP (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-05-03 | — | — | US | disclosed |
| WO-2007050721-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, ACHE, CHRM2 | CLK4 2228/4885RXRA 2620/4885RXRB 2732/4885 |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | CLK4 3504/4885RXRA 847/4885RXRB 1041/4885 |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | CLK4 1127/4885RXRA 928/4885RXRB 798/4885 |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | CLK4 2228/4885RXRA 2620/4885RXRB 2732/4885 |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | CLK4 1082/4885RXRA 1089/4885RXRB 1294/4885 |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CLK4 1127/4885RXRA 928/4885RXRB 798/4885 |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | CLK4 3796/4885RXRA 287/4885RXRB 608/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | CLK4 542/4885RXRA 3455/4885RXRB 3838/4885 |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | CLK4 2228/4885RXRA 2620/4885RXRB 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.